Tuesday, August 27, 2013

Tumour tablet new hope for cancer patients: Daily pill could shrink facial growths

  • New pill could help patients with severe skin cancer
  • Daily tablet shrinks facial growths which cannot be removed




  • Tumour tamer: The pill stops signals to the cells which tells them to grow
    Tumour tamer: The pill stops signals to the cells which tells them to grow
    A daily pill could offer new hope to patients with a disfiguring form of skin cancer.
    Tumours on the face and neck that cannot be  removed using routine treatments can now be shrunk using the simple tablet.
    It works by blocking the messages in cells that tell tumours to grow.
    The drug, vismodegib, was licensed earlier this month and will now be available to NHS patients under the Government’s Cancer Drugs Fund, which provides patients with rapid access to new treatments.
    Basal cell carcinoma is the most common form of skin cancer, affecting about 100,000 people a year in  the UK.
    Normally triggered by excessive exposure to UV radiation such as sunlight, it is easily treated using radiotherapy or surgery and rarely proves fatal.
    But a small number of patients either do not spot the tumours growing, do not seek medical help, or have tumours in a position where they are hard to remove, such as near the eye.
    Each year doctors see about 700 patients who have tumours so large that it would prove disfiguring  to have them cut away.
     

    For some, the cancer will also have spread to other parts of the body.
    The growths often leave these patients isolated and depressed.
    The drug, which has the brand name Erivedge, shrank these tumours in up to half of patients and was also shown to halt the progression of the tumours for about nine months.
    Anti-growth: The medicine was licensed earlier this month and will now be available to NHS patients under the Government¿s Cancer Drugs Fund
    Anti-growth: The medicine was licensed earlier this month and will now be available to NHS patients under the Government¿s Cancer Drugs Fund

    Dr Harpal Kumar, chief executive of Cancer Research UK, said: ‘This drug is a major advance  for the treatment of this disease, providing advanced basal cell carcinoma  patients with a new treatment option.
    ‘This is great news for patients.’
    Dr John Lear, consultant dermatologist at Central Manchester University Hospitals, who worked on the clinical trial of the  new drug, said that it  offered patients a ‘promising new outlook’.
    Roche, which makes the drug, said side effects include nausea, hair loss and muscle spasms and that effects on the foetus meant  it could not be given to pregnant women


    Read more: http://www.dailymail.co.uk/health/article-2401381/Tumour-tablet-new-hope-cancer-patients-Daily-pill-shrink-facial-growths.html#ixzz2dCfFwSU6 
    Follow us: @MailOnline on Twitter | DailyMail on Facebook